|
From: ironjustice@aol.com on 15 Sep 2006 17:58 <<snip>> suggests that iron reduction therapy by phlebotomy will be one of the promising therapies for NASH <<snip>> Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K, Nakashima T, Okanoue T Hepatol Res. 2006 Sep 11; Increased hepatic iron deposition may play a role in the pathogenesis of nonalcoholic steatohepatitis (NASH). This study aimed to test whether iron removal by phlebotomy improves serum transaminase activities in patients with NASH. Eleven patients (six males and five females) with biopsy-proven NASH underwent phlebotomy biweekly until they reached near-iron deficiency (NID) (serum ferritin concentration lower than or equal to 30ng/ml). Nine patients completed this study. Serum ferritin levels in these patients fell from 563+/-322 to 18+/-9ng/ml (p=0.001). The treatment reduced mean serum alanine aminotransferase (ALT) activity from 126+/-47 to 56+/-17IU/l (p=0.002). Their weight did not change significantly throughout the study period. Although two patients withdrew from the study, none was affected by any side effects of repeated phlebotomy that required discontinuing the treatment. In conclusion, this pilot study suggests that iron reduction therapy by phlebotomy will be one of the promising therapies for NASH. ----------------------------------------------------------------------------------- Advanced fibrosis is reversible In contrast with the traditional view that cirrhosis is an irreversible disease, recent evidence indicates that even advanced fibrosis is reversible (122). In experimentally induced fibrosis, cessation of liver injury results in fibrosis regression (123). In humans, spontaneous resolution of liver fibrosis can occur after successful treatment of the underlying disease. This observation has been described in patients with iron and copper overload, alcohol- induced liver injury, chronic hepatitis C, B, and D, hemochromatosis, secondary biliary cirrhosis, NASH, and autoimmune hepatitis (19, 122, 124,125, Sl, S2) (Figure 4). It may take years for significant regression to be achieved; the time varies depending on the underlying cause of the liver disease and its severity. Chronic HCV infection is the most extensively studied condition, and therapy (IFN-a plus ribavirin) with viral clearance results in fibrosis improvement. Importantly, nearly half of patients with cirrhosis exhibit reversal to a significant degree (90). Whether this beneficial effect is associated with improvements in long-term clinical outcome, incl\uding decreased portal hypertension, is unknown. http://www.rednova.com/news/display/?id=134481&source=r_health --------------------------------------------------------------------------- Who loves ya. Tom Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
|
Pages: 1 Prev: problems Next: Iron deposition / initiation and perpetuation of liver fibrosis |